Losartan
On July 15, Legacy Pharmaceutical expanded its consumer-level recall of three repackaged lots of losartan tablets 50 mg (NDC 68645-494-54) to include one additional lot. This recall was prompted by Torrent Pharmaceuticals's nationwide recall of losartan tablets, which were found to contain trace amounts of N-nitroso N-methyl 4-amino butyric acid (NMBA), a potential human carcinogen.
The product is used to treat high blood pressure and congestive heart failure and is packaged in 30-count bottles.
The affected losartan includes four repackaged lots numbers (three initial repackaged lots and one expanded repackaged lot): 180190, 180191, 181597, and 181598.
To date, Legacy has not received any reports of adverse events related to this recall.
